FeesSafety
Pluang+

Selinexor trial data for myelofibrosis and multiple myeloma to be presented at ASH 2026.

Market News
04 Nov 2026, 16:01 WIB
PRNewsWire
View Source
Bullish
Selinexor trial data for myelofibrosis and multiple myeloma to be presented at ASH 2026.

Karyopharm Therapeutics announced that data from its Phase 3 SENTRY trial and Phase 2 SENTRY-2 trial evaluating selinexor in myelofibrosis patients will be presented orally at ASH 2026, highlighting promising clinical activity. Additionally, data from a trial combining selinexor with other therapies in multiple myeloma will be shown as a poster. These presentations underscore selinexor's potential as a treatment option for myelofibrosis and multiple myeloma, with ongoing studies assessing its efficacy and safety. The findings could influence future treatment approaches for these blood cancers.

Karyopharm's presentation of selinexor data in myelofibrosis and multiple myeloma provides context for health-sector activity on Pluang. For readers following health stocks, here is Pluang's market snapshot as of Nov 04, 2026 19:41 WIB: out of 150 priced health-sector US stocks, 121 rose and 23 fell. Notable movers include MDLN at USD 37.50 with a 10.00% gain and 98% buy order activity, NUWE down 9.98% at USD 5.32 with 100% sell orders, and OSCR up 8.61% at USD 35.20 with 84% buy orders. The highest one-day gain was MDLN's 10.00%.

More News

Kelly Technology + Motion Recruitment named Leader by Everest Group for US IT staffing and consulting excellence

Kelly Technology + Motion Recruitment named Leader by Everest Group for US IT staffing and consulting excellence

Kelly Technology + Motion Recruitment, a division of Kelly Services, has been recognized as a Leader on Everest Group's 2026 U.S. IT Contingent Talent and Strategic Solutions PEAK Matrix® for its expertise in specialized IT staffing, consulting, and ...

Market News
Bullish
15 minutes ago
Sutro Biopharma to present at multiple investor conferences in November and December 2026

Sutro Biopharma to present at multiple investor conferences in November and December 2026

Sutro Biopharma, a clinical-stage oncology company specializing in antibody drug conjugates (ADCs), announced its participation in several investor conferences in November and December 2026, including events hosted by Stifel, Truist Securities, UBS, ...

Market News
Neutral
1 hour ago
etoro acquires Argentine fintech LB Finanzas to expand in Latin America

etoro acquires Argentine fintech LB Finanzas to expand in Latin America

etoro has agreed to acquire LB Finanzas, a leading Argentine all-in-one financial app, to strengthen its presence in Latin America's fast-growing fintech market. LB Finanzas offers integrated investing and payment solutions, catering to Argentine ret...

Company Fundamentals
Bullish
1 hour ago
JD.com to release Q3 2026 financial results on Nov 17 with a management call scheduled.

JD.com to release Q3 2026 financial results on Nov 17 with a management call scheduled.

JD.com announced it will publish its unaudited financial results for the third quarter of 2026 on November 17, before the U.S. market opens. The company's management will hold a conference call the same day to discuss the results, providing investors...

Company Fundamentals
Neutral
4 hours ago
KE Holdings to release Q3 2026 financial results on Nov 16 with a live earnings call.

KE Holdings to release Q3 2026 financial results on Nov 16 with a live earnings call.

KE Holdings Inc., a major online and offline housing platform in China, will announce its unaudited financial results for the third quarter of 2026 on November 16 before the U.S. market opens. The company will host an earnings conference call at 7:00...

Company Fundamentals
Neutral
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App